A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 microg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers.

Trial Profile

A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 microg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2012

At a glance

  • Drugs Yersinia pestis vaccine (Primary)
  • Indications Plague
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Planned end date changed from 1 Dec 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top